InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,528.00
(
0.90%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
72.91
(
0.00%
)
Bitcoin
69,015.17
(
-0.43%
)
Post# of 253511
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

rwwine

Send PM Follow Ignore
Followers 11
Posts 885
Boards Moderated 0
Alias Born 10/27/2003

rwwine

Re: None

Friday, 05/17/2024 2:01:16 PM

Friday, May 17, 2024 2:01:16 PM

Post# of 253511
Amgen; Today, the U.S. FDA approved Amgen’s delta-like ligand 3-targeting Bispecific T-cell Engager (BiTE®) immunotherapy in adults with extensive-stage small cell lung cancer (ES-SCLC).

Amgen is proud to deliver the first targeted immunotherapy to this patient population.

🔗 Press release: https://amgen.ly/3X35AWL
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up